Ameriprise
PHAT icon

Ameriprise’s Phathom Pharmaceuticals PHAT Stock Holding History

Ameriprise’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.82M Buy
254,219
+68,475
+37% +$865K ﹤0.01% 2789
2025
Q4 		$3.08M Sell
185,744
-368,846
-67% -$5.27M ﹤0.01% 2768
2025
Q3 		$6.53M Buy
554,590
+373,739
+207% +$3.86M ﹤0.01% 2228
2025
Q2 		$1.73M Buy
+180,851
New +$1M ﹤0.01% 3017
2024
Q1 		– Sell
-82,244
Closed -$751K – 3937
2023
Q4 		$751K Buy
82,244
+70,842
+621% +$610K ﹤0.01% 3302
2023
Q3 		$118K Buy
+11,402
New +$156K ﹤0.01% 3780

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return